Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.
Anatara recently released an exciting announcement to the market having received statistically significant efficacy data from their in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product. GaRP is a proprietary dietary supplement designed to restore and maintain a healthy human gut and microbiome.